NasdaqGS:TNYABiotechs
Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise
Tenaya Therapeutics (TNYA) is back in focus after updating investors on its heart disease gene therapy programs, outlining 2026 clinical milestones alongside a recent US$60 million capital raise that extends its cash runway.
See our latest analysis for Tenaya Therapeutics.
At a recent share price of US$0.72, Tenaya’s 1 day share price return of 1.95% follows a 90 day share price return decline of 57.39% and a 1 year total shareholder return decline of 44.07%. This suggests that near term...